Multiple Myeloma | eHealth News

For patients with newly diagnosed multiple myeloma

Study Supports Minimal Residual Disease As End Point in Myeloma

HealthDay.com - Sep 16, 2016 0

MRD-negative status linked to favorable progression-free, overall survival in multiple myeloma

$Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma$

Survival Up With Daratumumab in Relapsed Multiple Myeloma

HealthDay.com - Aug 24, 2016 0

Longer progression-free survival seen with daratumumab plus bortezomib and dexamethasone

1...6 78Page 8 of 8

Tag: Multiple Myeloma

Study Supports Minimal Residual Disease As End Point in Myeloma

Survival Up With Daratumumab in Relapsed Multiple Myeloma

EVEN MORE NEWS

Texas Sues Tylenol Over Alleged Autism Link

25 States Sue USDA to Keep Food Stamp Benefits From Stopping

Sugar Restriction in Early Life Tied to Cardiovascular Disease Benefits in...

POPULAR CATEGORY